Chapter

Adjuvant Therapies of Cancer

Volume 80 of the series Recent Results in Cancer Research pp 254-258

Clinical Trials of Chemotherapy and Chemoimmunotherapy in Primary Malignant Melanoma

  • C. JacquillatAffiliated withInstitut de Recherches sur les Mélanomes Malins, Lariboisière Saint-Louis, Unité de Chimiothérapie
  • , P. BanzetAffiliated withInstitut de Recherches sur les Mélanomes Malins, Lariboisière Saint-Louis, Unité de Chimiothérapie
  • , J. MaralAffiliated withInstitut de Recherches sur les Mélanomes Malins, Lariboisière Saint-Louis, Unité de Chimiothérapie

* Final gross prices may vary according to local VAT.

Get Access

Summary

We report here two randomized prospective clinical trials of adjuvant treatment in the management of primary malignant melanoma of Clark’s level III, IV or V. All patients had curative resection of the primary tumor. In the first trial, 117 patients were randomized between control (surgery alone) systemic chemotherapy and intraarterial chemotherapy. Intraarterial chemotherapy consisted of DTIC 80 mg/m2 + 8 days prior to surgery. Systemic chemotherapy consisted of courses of vinblastine (6 mg/m2), thiotepa (6 mg/m2), rufocromycine (60 M£/m2)> methotrexate (15 mg/m2) on day 1, and procarbazine (30 mg/m12 x 7 days. Courses were repeated every 2 weeks x 6, then every 4 weeks x 15. Twenty-two of 55 patients relapsed in the control group versus 22 of 67 in the chemotherapy group (NS). For male patients, the difference in disease-free survival was significant (P < 0.005, log rank test), though not in women.

In the second trial, 352 patients were entered from July, 1976. Men were randomized between chemotherapy and chemoimmunotherapy. Women were randomized between surgery alone and chemoimmunotherapy. Chemotherapy was identical, except for the addition of DTIC (300 mg/m2) for each course. Immunotherapy consisted of BCG every 4 weeks and C. parvum every week. Immunotherapy seemed to be of no additional benefit.